Presentations and Postersby Voluntary Organization JBCRG
CREATE-X (JBCRG-04): A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X , JBCRG-04)
CREATE-X (JBCRG-04): A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X , JBCRG-04)
2015 SABCS Oral
Phase I/II pharmacokinetics/pharmacodynamics study of irinotecan and S-1 for recurrent/metastatic breast cancer in patients with select UGT1A1 genotypes (The JBCRG-M01 study)
Shigehira Saji, Hiroshi ishiguro, Shogo Nomura, Hiroji Iwata, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi, Japan Breast Cancer Research Group
2016.10 ESMO Poster Copenhagen
Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04)
Shoichiro Ohtani, Norikazu Masuda, Young-Hyuck Im, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim, Yasuhiro Yanagita, Shintaro Takao, Shinji Ohno, Kenjiro Aogi, Hiroji Iwata, Katsuhide Yoshidome, Reiki Nishimura, Eun Sook Lee, Isao Yokota, Yasuo Ohashi, Soo-Jung Lee, Masakazu Toi
2013 SABCS Poster
Comparison of Molecular characterization of ER+early-stage cancer by standardized quantitative RT-PCR analysis between Japanese and North American populations.
Masuda N, Yamanaka T, Iwata H, Ohno S, Nakamura S, Kashiwaba M, Kamigaki S, Aogi K, Ueno T, Toi M; Japan Breast Cancer Research Group (JBCRG)
ASCO Breast, San Francisco, USA, 2009年10月
Neoadjuvant docetaxel (DOC 75) followed by fluorouracil, epirubicin, cyclophosphamide (FEC 100) in primary operable breast cancer: Results of a multicenter phase II trial: JBCRG03 trial
Sato N, Iwata H, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Toi M; Japan Breast Cancer Research Group (JBCRG)
6th European Breast Cancer Conference, Poster, Berlin (Germany), Apr. 2008
The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer.
Nakamura S, Toi M, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F; Japan Breast Cancer Research Group (JBCRG)
5th European Breast Cancer Conference, Nice (France), Mar. 2006
Premature ovarian disfunction induced by neopadjuvantr chemotherapy (FEC followed by docetaxel) for breast cancer
Shinano Hitomi, Hamaoka Tsuyoshi, Nakamura Seigo, Toi Masakazu, Kuroi Katsumasa; Japan Breast Cancer Research Group (JBCRG).
3rd Organisation for Oncology and Translational Research, Hong Kong, Oral, Sep. 2006
Significance of HER2 for predicting pathological complete response to preoperative treatment with FEC followed by docetaxel
Toi M, Nakamura S, Takatsuka Y, Kuroi K, Iwata H, Ohno S, Masuda N, Tsuda H, Kurosumi M, Akiyama F；Japan Breast Cancer Research Group (JBCRG).
29th San Antonio Breast Cancer Symposium, Poster, San Antonio (USA), Dec. 2006
Feasibility and efficacy of phase II trial of sequential preoperative FEC 100 followed by Docetaxel 100 in primary operable breast cancer.
Nakamura S, Masuda N, Iwata H, Toi M, Kuroi K, Akiyama F; Japan Breast Cancer Research Group (JBCRG)
2nd Organisation for Oncology and Translational Research, Tokyo, Nov. 2005
Cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF – DOC) as preoperative chemotherapy in primary operable breast cancer.
Kuroi K, Toi M, Takatsuka Y, Iwata H, Ohno S, Kusama M, Shin E, Hisamatsu K, Yamazaki K, Sato Y, Masuda N, Kaise H, Akiyama F, Nakamura S; Japan Breast Cancer Research Group (JBCRG)
15th International Congress on Anti Cancer Treatment, Paris (France), Feb. 2004